The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy
Abstract
BACKGROUND: One of the newest methicillin-resistant Staphylococcus aureus (MRSA) antibiotics to receive FDA approval is ceftaroline fosamil, a member of a new subclass of cephalosporins with unique activity against MRSA. However, ceftaroline is currently only FDA approved for complicated skin/soft tissue infections and community-acquired pneumonia; there are currently no clinical data regarding its use in MRSA bacteraemia and endocarditis. We report a series of six patients in which ceftaroline was utilized as salvage monotherapy in persistent MRSA bacteraemia or endocarditis. METHODS: Using pharmacy records, 11 ceftaroline-treated patients were identified between January 2011 and November 2011 at University Health System and the South Texas Veterans Health Care System in San Antonio, TX, USA. All cases were reviewed and six patients received ceftaroline therapy for MRSA bacteraemia or endocarditis due to persistent or recurrent bacteraemia while on standard antibiotics (vancomycin or daptomycin). RESULTS: All six patients experienced rapid clearance of their bacteraemia after starting ceftaroline. In the case of endocarditis for which the patient subsequently developed heart failure and required valve replacement, there was no evidence of growth from cultures taken from the excised valve, suggesting sterilization within 13 days of starting ceftaroline. CONCLUSIONS: Ceftaroline exhibits potent anti-MRSA activity in both in vitro and animal studies, including rabbit endocarditis models; however, the lack of clinical data has limited its use in bacteraemia and endovascular infections in humans. We hope that this series serves as an initial stepping stone for further evaluation of this compound for more invasive infections due to MRSA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
(2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir353 · Cited by 172
van Hal, S. J., Paterson, D. L., & Gosbell, I. B. (2010) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-010-1128-3 · Cited by 148
Jacqueline, C., Caillon, J., Mabecque, V. L., Miegeville, A.-F., Hamel, A., Bugnon, D., Ge, J. Y., & Potel, G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01242-06 · Cited by 121
Ceftaroline: A New Cephalosporin with Activity Against Resistant Gram‐Positive Pathogens
Steed, M. E., & Rybak, M. J. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.4.375 · Cited by 104
Ceftaroline: a comprehensive update
Kaushik, D., Rathi, S., & Jain, A. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.01.017 · Cited by 47
Karlowsky, J. A., Adam, H. J., DeCorby, M. R., Lagacé-Wiens, P. R. S., Hoban, D. J., & Zhanel, G. G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01787-10 · Cited by 45
Vidaillac, C., Leonard, S. N., & Rybak, M. J. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.02.006 · Cited by 24
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Management Considerations in Infective Endocarditis: A Review
Wang, A., Gaca, J. G., & Chu, V. H. (2018) · JAMA · doi:10.1001/jama.2018.7596 · Cited by 368
Lin, J. C., Fierer, J., Aung, G., Johns, S., Thomas, A., Jahng, M., Fierer, J., & Fierer, J. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-012-0449-9 · Cited by 109
Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy
Casapao, A. M., Davis, S. L., Barr, V. O., Klinker, K. P., Goff, D. A., Barber, K. E., Kaye, K. S., Mynatt, R. P., Molloy, L. M., Pogue, J. M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02371-13 · Cited by 108
Metadata
- Authors
- Ho, T. T., Cadena, J., Childs, L. M., Gonzalez-Velez, M., & Lewis, J. S.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Audie L. Murphy Memorial VA Hospital (US)
- Corresponding author
- Lewis, J. S.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-02-06
- Volume
- 67
- Issue
- 5
- Pages
- 1267-1270
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2160238480
- Semantic Scholar
- 55ea9e4c7330442b65d09801701017f060105f62
- Cited by
- 130
- References
- 8
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 7 · 2019: 10 · 2018: 7 · 2017: 20 · 2016: 16 · 2015: 12 · 2014: 19 · 2013: 18 · 2012: 3
- FWCI
- 11.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- methicillin-resistant Staphylococcus aureus, ceftaroline fosamil, MRSA bacteremia, infective endocarditis, salvage therapy, persistent bacteraemia, recurrent bacteraemia, vancomycin, daptomycin, heart failure, valve replacement, cephalosporins
- MeSH terms
- Ceftaroline, Adult, Anti-Bacterial Agents, Cephalosporins, Endocarditis, Bacterial, Female, Humans, Male, Middle Aged, Staphylococcal Infections, Texas, Bacteremia, Salvage Therapy, Treatment Outcome, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.